Monte Rosa Therapeutics EPS
The Earnings per Share (EPS) of Monte Rosa Therapeutics (GLUE) as of Oct 5, 2026 is -0.59 USD. In the previous year, Earnings per Share (EPS) was -1.18 USD — a change of -50.20% (higher).
Get this data via API
Financial Data API
EPS
-0.59USD
YoY
-50.20%
Last updated:
The Monte Rosa Therapeutics EPS history
3 Years
10 Years
25 Years
Max
| YEAR | EPS | YoY |
|---|---|---|
| est | -2.17USD | -3.07% |
| est | -2.24USD | +29.10% |
| est | -1.73USD | -11.89% |
| est | -1.97USD | +33.00% |
| est | -1.48USD | +151.04% |
| -0.59USD | -50.20% | |
| -1.18USD | -50.23% | |
| -2.38USD | +7.14% | |
| -2.22USD | +37.99% | |
| -1.61USD | -2.56% | |
| -1.65USD | +805.93% | |
| -0.18USD | — |
Monte Rosa Therapeutics Stock analysis
Frequently Asked Questions about Monte Rosa Therapeutics stock
Earnings per Share (EPS) of Monte Rosa Therapeutics is -0.59 USD in 2026.
Earnings per Share (EPS) of Monte Rosa Therapeutics changed from -1.18 USD to -0.59 USD, representing a -50.20% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.
Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.
EPS = Net Income / Shares Outstanding
Income Statement — Monte Rosa Therapeutics
All Key Metrics — Monte Rosa Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth